Cargando…
Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, ai...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473227/ https://www.ncbi.nlm.nih.gov/pubmed/30744192 http://dx.doi.org/10.3390/tropicalmed4010033 |
_version_ | 1783412381709238272 |
---|---|
author | Diefenbach-Elstob, Tanya Guernier, Vanina Burgess, Graham Pelowa, Daniel Dowi, Robert Gula, Bisato Puri, Munish Pomat, William McBryde, Emma Plummer, David Rush, Catherine Warner, Jeffrey |
author_facet | Diefenbach-Elstob, Tanya Guernier, Vanina Burgess, Graham Pelowa, Daniel Dowi, Robert Gula, Bisato Puri, Munish Pomat, William McBryde, Emma Plummer, David Rush, Catherine Warner, Jeffrey |
author_sort | Diefenbach-Elstob, Tanya |
collection | PubMed |
description | Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, aiming to identify the proportion of DR-TB, and characterise Mycobacterium tuberculosis (MTB) drug resistance-associated gene mutations. Sputum samples were investigated for MTB infection using published molecular methods. DNA from MTB-positive samples was amplified and sequenced, targeting the rpoB and katG genes to identify mutations associated with rifampicin and isoniazid resistance respectively. A total of 240 sputum samples were collected at Balimo District Hospital (BDH). Of these, 86 were classified as positive based on the results of the molecular assays. For samples where rpoB sequencing was successful, 10.0% (5/50, 95% CI 4.4–21.4%) were considered rifampicin-resistant through detection of drug resistance-associated mutations. We have identified high rates of presumptive DR-TB in the Balimo region of Western Province, PNG. These results emphasise the importance of further surveillance, and strengthening of diagnostic and treatment services at BDH and throughout Western Province, to facilitate detection and treatment of DR-TB, and limit transmission in this setting. |
format | Online Article Text |
id | pubmed-6473227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64732272019-04-29 Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea Diefenbach-Elstob, Tanya Guernier, Vanina Burgess, Graham Pelowa, Daniel Dowi, Robert Gula, Bisato Puri, Munish Pomat, William McBryde, Emma Plummer, David Rush, Catherine Warner, Jeffrey Trop Med Infect Dis Article Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, aiming to identify the proportion of DR-TB, and characterise Mycobacterium tuberculosis (MTB) drug resistance-associated gene mutations. Sputum samples were investigated for MTB infection using published molecular methods. DNA from MTB-positive samples was amplified and sequenced, targeting the rpoB and katG genes to identify mutations associated with rifampicin and isoniazid resistance respectively. A total of 240 sputum samples were collected at Balimo District Hospital (BDH). Of these, 86 were classified as positive based on the results of the molecular assays. For samples where rpoB sequencing was successful, 10.0% (5/50, 95% CI 4.4–21.4%) were considered rifampicin-resistant through detection of drug resistance-associated mutations. We have identified high rates of presumptive DR-TB in the Balimo region of Western Province, PNG. These results emphasise the importance of further surveillance, and strengthening of diagnostic and treatment services at BDH and throughout Western Province, to facilitate detection and treatment of DR-TB, and limit transmission in this setting. MDPI 2019-02-10 /pmc/articles/PMC6473227/ /pubmed/30744192 http://dx.doi.org/10.3390/tropicalmed4010033 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Diefenbach-Elstob, Tanya Guernier, Vanina Burgess, Graham Pelowa, Daniel Dowi, Robert Gula, Bisato Puri, Munish Pomat, William McBryde, Emma Plummer, David Rush, Catherine Warner, Jeffrey Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title | Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title_full | Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title_fullStr | Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title_full_unstemmed | Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title_short | Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea |
title_sort | molecular evidence of drug-resistant tuberculosis in the balimo region of papua new guinea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473227/ https://www.ncbi.nlm.nih.gov/pubmed/30744192 http://dx.doi.org/10.3390/tropicalmed4010033 |
work_keys_str_mv | AT diefenbachelstobtanya molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT guerniervanina molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT burgessgraham molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT pelowadaniel molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT dowirobert molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT gulabisato molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT purimunish molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT pomatwilliam molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT mcbrydeemma molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT plummerdavid molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT rushcatherine molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea AT warnerjeffrey molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea |